Back to search

Article

Serum Proteomic Profile of Advanced NSCLC and Exploration of Efficacy Markers for Anti-Angiogenic Drugs

2024-09-25

Abstract excerpt

Lung cancer is prevalent worldwide. Antiangiogenic therapy is an important treatment strategy for patients with advanced or recurrent non-small cell lung cancer (NSCLC). Currently, there is still a lack of reliable markers for efficacy testing and evaluation of antiangiogenic efficacy. We used label-free quantitative proteomics technology to read a total of 516 proteins in the plasma proteome of advanced NSCLC and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
fc989fc2-a23f-51c8-9a4f-f55c59f8f20d
DOI
10.22541/au.172727327.79280645/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Serum Proteomic Profile of Advanced NSCLC and Exploration of Efficacy Markers for Anti-Angiogenic DrugsDOI 10.22541/au.172727327.79280645/v1
Angiogenic Factor-Based Signature Predicts Prognosis and Immunotherapy Response in Non-Small-Cell Lung CancerSemantic proximity
Comprehensive Analysis for Anti-Cancer Target-Indication Prioritization of Placental Growth Factor Inhibitor (PGF) by Use of Omics and Patient Survival DataSemantic proximity
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patientsSemantic proximity
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapySemantic proximity
A new clustering: Angiogenesis-Associated Molecular Classification of Lung adenocarcinomaSemantic proximity
Bioinformatics analysis of NSCLC multi-omics dataSemantic proximity
Identification and validation of plasma exosomal FGL1 as an early diagnostic biomarker for non-small cell lung cancerSemantic proximity
Novel risk prediction models for prognosis and immunotherapies of NSCLC based on coagulation and fibrinolysis-related genesSemantic proximity
Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implicationsSemantic proximity
Identification of promising lung cancer drug targets from human plasma proteins: Mendelian randomization, single-cell RNA sequencing analysisSemantic proximity
A novel decision-making tool for first-line treatment selection in metastatic non-small cell lung cancer based on plasma proteome profilingSemantic proximity
SPP1, a potential therapeutic target and biomarker for lung cancer: functional insights through computational studiesSemantic proximity
Select a neighboring publication to make it the new centre.